NCT00674947View on ClinicalTrials.gov

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Solid Tumors

Interventions

DRUG

BIIB015

IV infusion once every 3 weeks until disease progression or unacceptable toxicity

Trial Locations (3)

Unknown

Research Site, Santa Monica

Research Site, Philadelphia

Research Site, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY

NCT00674947 - A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | Biotech Hunter | Biotech Hunter